CJC-1295 DAC peptide is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH). Researchers believe it may increase endogenous growth hormone (GH) secretion by mimicking GHRH function. It is currently the shortest known GHRH analog that can still stimulate GH release from pituitary somatotrophs.
Amino Acid Sequence Modifications: Four amino acids in the original 29-amino-acid GHRH sequence are replaced to improve pharmacokinetic properties and extend half-life.
DAC Component: The DAC moiety, a lysine derivative (N-ε-3-maleimidopropionylamide) attached to the C-terminal, binds plasma proteins, further prolonging the peptide’s half-life.
Half-Life: With DAC integration, CJC-1295 DAC has a half-life of approximately 8 days while retaining high affinity for the GHRH receptor.
Non-DAC CJC-1295 still has research value. For example, it may synergize with Ipamorelin, combining a GHRH analog with a peptide that activates the somatostatin receptor in the pituitary, enhancing GH synthesis.
Common names for CJC-1295 DAC include:
CJC-1295 with DAC
DAC:GRF
Long-acting GHRH analog
Synthetic GHRH analog
Studies suggest CJC-1295 DAC may influence:
Fat reduction: By promoting energy utilization from adipose tissue.
Muscle gain: Likely via enhanced protein synthesis.
Bone density improvement: Supporting skeletal growth and connective tissue health, potentially reducing injury risk.
Sleep enhancement: May act on sleep centers in the nervous system.
GH and IGF-1: CJC-1295 DAC stimulates pituitary GH release, indirectly increasing IGF-1 levels in the liver and other tissues.
Signaling Pathway: GH binding to its receptor activates the JAK-STAT pathway. STAT proteins enter the nucleus and bind specific DNA sequences, promoting IGF-I gene transcription.
IGF-1 Function: IGF-1 is a potent hormone that promotes cell proliferation and tissue growth, enhancing protein synthesis and tissue strengthening.
Molecular Formula: C152H252N44O42
Molecular Weight: 3367.95 g/mol
Other Names: DAC-substituted GRF 1-29
First Study: Subjects received four escalating doses of CJC-1295 DAC or placebo.
Second Study: Subjects received repeated doses of a single concentration of CJC-1295 DAC.
GH Levels: CJC-1295 DAC significantly increased average GH levels, with reported elevations of 2–10 fold over 6 days or more.
IGF-1 Levels: Average IGF-I levels increased 1.5–3 fold within 9–11 days and may remain elevated for at least two weeks.
Cumulative Effect: Repeated exposure maintained IGF-I levels above baseline for up to 28 days.